- Home
- CGNT vs DNA Comparison
CGNT vs DNA Comparison
Compare CGNT & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- DNA
- Stock Information
- Founded
- CGNT 2020
- DNA 2008
- Country
- CGNT Israel
- DNA United States
- Employees
- CGNT N/A
- DNA N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CGNT Technology
- DNA Health Care
- Exchange
- CGNT Nasdaq
- DNA Nasdaq
- Market Cap
- CGNT 657.1M
- DNA 731.1M
- IPO Year
- CGNT N/A
- DNA N/A
- Fundamental
- Price
- CGNT $8.73
- DNA $10.21
- Analyst Decision
- CGNT Hold
- DNA Hold
- Analyst Count
- CGNT 1
- DNA 2
- Target Price
- CGNT N/A
- DNA $9.50
- AVG Volume (30 Days)
- CGNT 274.4K
- DNA 1.6M
- Earning Date
- CGNT 09-09-2025
- DNA 11-11-2025
- Dividend Yield
- CGNT N/A
- DNA N/A
- EPS Growth
- CGNT N/A
- DNA N/A
- EPS
- CGNT N/A
- DNA N/A
- Revenue
- CGNT $376,566,000.00
- DNA $230,815,000.00
- Revenue This Year
- CGNT $14.94
- DNA N/A
- Revenue Next Year
- CGNT $9.57
- DNA $13.73
- P/E Ratio
- CGNT N/A
- DNA N/A
- Revenue Growth
- CGNT 14.04
- DNA 25.21
- 52 Week Low
- CGNT $6.21
- DNA $5.00
- 52 Week High
- CGNT $11.66
- DNA $16.85
- Technical
- Relative Strength Index (RSI)
- CGNT 48.43
- DNA 39.56
- Support Level
- CGNT $8.15
- DNA $10.11
- Resistance Level
- CGNT $8.81
- DNA $11.97
- Average True Range (ATR)
- CGNT 0.30
- DNA 0.78
- MACD
- CGNT 0.00
- DNA -0.22
- Stochastic Oscillator
- CGNT 40.85
- DNA 3.36
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.